{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29","upperLimit":"165","value":"81"},{"groupId":"OG001","lowerLimit":"23","upperLimit":"260","value":"100"},{"groupId":"OG002","lowerLimit":"14","upperLimit":"410","value":"124"},{"groupId":"OG003","lowerLimit":"32","upperLimit":"136","value":"95"},{"groupId":"OG004","lowerLimit":"64","upperLimit":"127","value":"77.5"},{"groupId":"OG005","lowerLimit":"36","upperLimit":"351","value":"79"},{"groupId":"OG006","lowerLimit":"64","upperLimit":"282","value":"108"},{"groupId":"OG007","lowerLimit":"35","upperLimit":"311","value":"95.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"20"}],"units":"Participants"}],"description":"Interval of time from the start of study drug treatment to the date of disease progression, where disease progression is defined by 2007 IWG criteria as any new lesion or increase by ≥ 50% of previously involved sites from nadir. TTP was censored at the time of study withdrawal for hematopoietic stem cell transplant, at the time of study treatment withdrawal (or at the time of crossover from monotherapy to combination therapy), or at the time of study termination, whichever was earliest, for patients without reported disease progression.","dispersionType":"Full Range","groups":[{"description":"Patients with relapsed or refractory EBV-positive diffuse large B-cell lymphoma treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG000","title":"Diffuse Large B-Cell Lymphoma"},{"description":"Patients with relapsed or refractory EBV-positive extranodal natural killer/T-cell lymphoma treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG001","title":"Extranodal Natural Killer/T-Cell Lymphoma"},{"description":"Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG002","title":"Peripheral T-Cell Lymphoma (Combination Therapy)"},{"description":"Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week","id":"OG003","title":"Peripheral T-Cell Lymphoma (Monotherapy)"},{"description":"Patients with relapsed or refractory EBV-positive Hodgkin lymphoma treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG004","title":"Hodgkin Lymphoma"},{"description":"Patients with relapsed or refractory EBV-positive post-transplant lymphoproliferative disorders treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG005","title":"Post-Transplant Lymphoproliferative Disorders"},{"description":"Patients with relapsed or refractory EBV-positive human immunodeficiency virus-associated lymphomas treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG006","title":"Human Immunodeficiency Virus-Associated Lymphomas"},{"description":"Patients with relapsed or refractory EBV-positive lymphomas other than those from the other cohorts treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG007","title":"Other EBV-Positive Lymphomas"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat Analysis Set, defined as all patients who were enrolled into the trial regardless of whether or not they received study treatment.\n\nThe study was not designed to make formal statistical comparisons of TTP between cohorts.","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"days"}